PATIENT‑ORIENTED ASSESSMENT OF BLOOD PRESSURE TELEMONITORING AND REMOTE COUNSELING IN HYPERTENSIVE PATIENTS: A PILOT PROJECT

Objective. To evaluate patient-oriented endpoints and antihypertensive effectiveness of blood pressure (BP) monitoring and distant counseling (TMDC) among outpatients with uncontrolled hypertension (HTN). Design and methods. Programs of TMDC with different duration of follow-up (1, 3, 6, 12 months) were developed (with obligatory initial and final clinic visits). The demand in TMDC was assessed by a preliminary survey among cardiologists (n = 73) and hypertensive patients (n = 540) referred to Almazov National Medical Research Centre. Patients with uncontrolled HTN who signed informed consent were enrolled in the study being assigned to TMDC or to the age, sex and BP level-matched control group; the latter ones were given standard recommendations (outpatient visits once every 3 months). None of the patients had any serious comorbidities requiring frequent face-to-face visits. On a baseline clinic visit TMDC patients were given detailed technical instructions on BP selfmonitoring and request for counseling through web-site and mobile application. Office BP levels were evaluated twice, at baseline and at the final clinic visit. In the TMDC group BP level, the frequency and reasons for the consultations were assessed. For evaluation of patient-reported outcomes questionnaires of the Hospital Anxiety and Depression Scale («HADS») and «SF-36» were provided at the first and final visits. Results. According to initial survey, 12 (16 %) of 73 cardiologists and 184 (34 %) among 540 patients at Almazov National Medical Research Centre gave a positive opinion regarding TMDC. Most patients (n = 129; 70 %) chose a three-month TMDC plan. Of these, 110 patients (74 men, mean age 51,2 ± 17,0 years) completed follow-up period; control group consisted of 80 sex-, age- and BP-matched patients. TMDC group demonstrated a more pronounced decrease in office systolic (SBP) and diastolic (DBP) BP levels as compared to the control group: Δ –22 ± 12,4 versus Δ –8,6 ± 22,4 mmHg for SBP (p = 0,005) and Δ –13,6 ± 10,8 versus Δ –7 ± 11,3 mm Hg for DBP (p = 0,02). At final visit target office BP level (< 140/90 mmHg) was achieved in 82 patients (75 %) and 16 patients (20 %) in the TMDC and control groups, respectively (χ 2 = 20,8; p < 0,01). For the entire follow-up period, everyone in TMDC group required at least 1 remote doctor’s advice and in 36 cases (33 %) antihypertensive therapy correction was necessary. Aside, TMDC group showed reduction in anxiety and depression according to HADS (–1,2 and –1,8 score, respectively, p < 0,05) and improvement in physical HRQoL (+ 9 ± 3,3 points SF-36, p = 0,04). Conclusion. Results demonstrated that a simple and safe telehealth tool for patients with uncontrolled HTN is easily applicable in routine daily clinical practice, provides additional antihypertensive effect and improves patientreported outcomes. However, it needs additional support measures for higher acceptance in routine practice.

arterial hypertension, self-monitoring, patient-reported outcomes, telemedicine, telemonitoring, adherence

1. Piepoli MF, Hoes AW, Agewall F, Albus C, Brotons C, Catapano AL et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of 10 Societies and by Invited Experts): Developed with the Special Contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prevent Cardiol. 2016;23(11): NP1-NP96. doi:10.1 177/2047487316653709

2. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Pres. 2014;23(1):3–16. doi:10.3109/08037051.2014.868629

3. Чазова И. Е., Жернакова Ю. В., Ощепкова Е. В. Шальнова С. А., Яровая Е. Б., Конради А. О. и др. Распространенность факторов риска сердечно-сосудистых заболеваний в российской популяции больных артериальной гипертонией. Кардиология. 2014;54(10):4–12 [Chazova IE, Zhernakova YuV, Oshchepkova EV, Shalnova SA, Yarovaya EB, Konradi AO et al. prevalence of cardiovascular risk factors in russian population of patients with arterial hypertension. Kardiologiia. 2014:54(10):4–12. In Russian] doi:10.18565/cardio.2014.10.4–12

4. Бойцов С. А., Баланова Ю. А., Шальнова С. А., Деев А. Д., Артамонова Г. В., Гатагонова Т. М. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2015;13(4): 4–14 [Boytsov SA, Balanova YA, Shalnova SA, Deev AD, Artamonova GV, Gatagonova TM et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Kardiovaskulyarnaya Terapiya i Profilaktika = Cardiovascular Therapy and Prevention. 2014;13(4):4–14. In Russian].

5. Ettehad D, Connor AE, Kiran A, Anderson SG, Callender T, Emberson J et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis. Lancet (London, England). 2016;387(10022): 957–967. doi:10.1016/S0140–6736(15)01225–8

6. Dongliang L, Li X, Wang L, Xu H, Tuo X, Jian Z. Current status of blood pressure control rate and antihypertensive drug use in the elderly coronary heart disease patients with diabetes mellitus and hypertension. Zhonghua Yi Xue Za Zhi. 2015,95 (33):2709–2714.

7. Redon J, Mourad JJ, Schmieder RE, Volpe M, Weiss TW. Why in 2016 Are patients with hypertension not 100 % controlled? A call to action. J Hypertens. 2016;34(8):1480–1488. doi:10.1097/HJH.0000000000000988

8. Padwal RS, Bienek A, McAlister FA, Campbell NR, Outcomes Research Task Force of the Canadian Hypertension Education Program. Epidemiology of hypertension in Canada: an update. Can J Cardiol. 2016;32(5):687–694. doi:10.1016/j. cjca.2015.07.734

9. Yoon SS, Carroll MD, Fryar CD. Hypertension prevalence and control among adults: United States, 2011–2014. NCHS Data Brief. 2015;220:1–8.

10. Bobrow K, Farmer AJ, Springer D, Shanyinde M, Yu LM, Brennan T et al. Mobile phone text messages to support treatment adherence in adults with high blood pressure (SMS-Text Adherence Support [StAR]): a single-blind, randomized trial. Circulation.2016;133(6):592–600. doi:10.1161/CIRCULATIONAHA.115.017530

11. Parati G, Omboni S, Bilo G. Why is out-of-office blood pressure measurement needed? Hypertension. 2009;54(2):181–187. doi:10.1161/HYPERTENSIONAHA.108.122853

12. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens. 2010;24 (12):779–785. doi:10.1038/jhh.2010.54

13. Hodges P. Heart failure: epidemiologic update. Critical Care Nursing Quarterly. 2009;32(1):24–32. doi:10.1097/01. CNQ.0000343131.27318.36

14. Steiner JF, Ho PM, Beaty BL, Dickinson LM, Hanratty R, Zeng C et al. Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circulation. Cardiovascular Quality and Outcomes. 2009;2(5):451–457. doi:10.1161/CIRCOUTCOMES.108.841635

15. Peacock E, Krousel-Wood M. Adherence to antihypertensive therapy. The Medical Clinics of North America. 2017;101(1):229– 245. doi:10.1016/j.mcna.2016.08.005

16. Kettani FZ, Dragomir A, Côté R, Roy L, Bérard A, Blais L et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40 (1):213–220. doi:10.1161/STROKEAHA.108.522193

17. Perreault S, Dragomir A, White L. Better adherence to antihypertensive agents and risk reduction of chronic heart failure. J Int Med. 2009;266(2):207–218.

18. Perreault S, Dragomir A, Roy L, Blais L, Lalonde L, Bérard A et al. Adherence level of antihypertensive agents in coronary artery disease. Br J Clin Pharmacol. 2010;69(1):74–84. doi:10.1111/ j.1365–2125.2009.03547.x

19. Hill MN, Miller NH, DeGeest S, American Society of Hypertension Writing Group. ASH Position Paper: Adherence and persistence with taking medication to control high blood pressure. J Clin Hypertens (Greenwich, Conn.) 2010;12(10):757–764. doi:10.1111/j.1751–7176.2010.00356.x

20. Tientcheu D, Ayers C, Das SR, McGuire DK, de Lemos JA, Khera A et al. Target organ complications and cardiovascular events associated with masked hypertension and white-coat hypertension: analysis from the Dallas Heart Study. J Am Coll Cardiol. 2015;66 (20):2159–2169. doi:10.1016/j.jacc.2015.09.007

21. Nwankwo T, Gindi R, Chen TC, Galinsky A, Miller I, Terry A et al. Comparison of blood pressure measurements obtained in the home setting: analysis of the health measures at home study. Blood Press Monit. 2016;21(6):327–334. doi:10.1097/MBP.0000000000000210

22. Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32 (7):1359–1366. doi:10.1097/HJH.0000000000000221

23. Parati G, Pickering TG. Home blood-pressure monitoring: US and European Consensus. Lancet (London, England) 2009;373 (9667):876–878. doi:10.1016/S0140–6736 (09)60526–2

24. Parati G, Omboni S. Role of home blood pressure telemonitoring in hypertension management: an update. Blood Press Monit. 2010;15(6):285–295. doi:10.1097/MBP. 0b013e328340c5e4

25. Lee CJ, Park S. The role of home blood pressure telemonitoring for blood pressure control. Pulse (Basel, Switzerland) 2016;4(2–3):78–84. doi:10.1159/000448375

26. Bonafini S, Fava C. Home blood pressure measurements: advantages and disadvantages compared to office and ambulatory monitoring. Blood Press. 2015;24(6):325–332. doi:10.3109/0803 7051.2015.1070599

27. eHealth Action Plan 2012–2020 — Innovative Healthcare for the 21st Century, http://ec.europa.eu/health//sites/health/files/ehealth/docs/com_2012_736_en.pdf.

28. About Digital Health. 2017. http://www.cocir.org/index.php?id=147.

29. About Telemedicine. 2017. http://www.cocir.org/index.php?id=103.

30. About mHealth. 2017. http://www.cocir.org/index.php?id=175.

31. Perroy AC. m-health in an age of e-health. Promises, challenges and liabilities Annales Pharmaceutiques Francaises. 2016;4(6):421–430. doi:10.1016/j.pharma.2016.03.002

32. European Commission. Green paper on Mobile Health (‘m-Health’). Brussels, 2014. Https://Ec.europa.eu/Digital- Agenda/En/News/Green-Papermobile-Health-Mhealth.

33. Cowie MR, Bax J, Bruining N, Cleland JG, Koehler F, Malik M et al. E-Health: a position statement of the European Society of Cardiology. Eur Heart J. 2016;37(1):63–66. doi:10.1093/ eurheartj/ehv416

34. WHO Library Cataloguing-in-Publication Data mHealth: new horizons for health through mobile technologies: second global survey on eHealth. WHO Global Observatory for eHealth. http://apps.who.int/iris/bitstream/10665/44607/3/9789244564257_rus.pdf?ua=1

35. http://www.itu.int/ITU-D/ict/material/FactsFigures2010.pdf

36. Suciu G, Suciu V, Martian A, Craciunescu R, Vulpe A, Marcu I et al. Big data, internet of things and cloud convergence-an architecture for secure E-Health applications. J Med Syst. 2015;39 (11):141. doi:10.1007/s10916–015–0327-y

37. Lo BPL., Henry I, Yang G-Z. Transforming health care: body sensor networks, wearables, and the Internet of things. IEEE Pulse 2016;7(1):4–8. doi:10.1109/MPUL.2015.2498474

38. Sawesi S, Rashrash M, Phalakornkule K, Carpenter JS, Jones JF. The impact of information technology on patient engagement and health behavior change: a systematic review of the literature. JMIR Med Informatics. 2016;4(1) doi:10.2196/medinform.4514

39. Omboni S, Ferrari R. The role of telemedicine in hypertension management: focus on blood pressure telemonitoring. Curr Hypertens Rep. 2015; 17(4): 535. doi:10.1007/s11906–015– 0535–3

40. US Department of Health and Human Services. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRe gulatoryInformation/Guidances/UCM193282.pdf

41. European Medicines Agency, Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health related quality of life (HRQL) measures in the evaluation of medicinal products. 2005. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003637.pdf

42. Thompson DR, Ski CF, Garside J, Astin F. A review of health-related quality of life patient-reported outcome measures in cardiovascular nursing. Eur J Cardiovasc Nurs. 2016;15(2): 114–125.

43. Mancia G, Parati G. Home blood pressure monitoring: a tool for better hypertension control. Hypertension. 2011;57(1):21–23. doi:10.1161/HYPERTENSIONAHA.110.163188

44. Agarwal R, Bills JE, Hecht TJW, Light RP. Role of Home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57(1):29–38. doi:10.1161/HYPERTENSIONAHA.110.160911

45. Stergiou GS, Karpettas N, Destounis A, Tzamouranis D, Nasothimiou E, Kollias A et al. Home blood pressure monitoring alone vs. combined clinic and ambulatory measurements in following treatment-induced changes in blood pressure and organ damage. Am J Hypertens. 2014;27(2):184–192. doi:10.1093/ajh/hpt206

46. Stergiou GS, Argyraki KK, Moyssakis I, Mastorantonakis SE, Achimastos AD, Karamanos VG et al. Home blood pressure is as reliable as ambulatory blood pressure in predicting target-organ damage in hypertension. Am J Hypertens. 2007;20(6):616–621. doi:10.1016/j.amjhyper.2006.12.013

47. Mutlu S, Sari O, Arslan E, Aydogan U, Doganer YC, Koc B. Comparison of ambulatory blood pressure measurement with home, office and pharmacy measurements: is arterial blood pressure measured at pharmacy reliable? J Eval Clin Pract. 2016;22 (1):40–45. doi:10.1111/jep.12424

48. Omboni S, Caserini M, Coronetti C. Telemedicine and M-Health in hypertension management: technologies, applications and clinical evidence. high blood pressure & cardiovascular prevention. Official J Ital Soc Hypertens. 2016;23(3):187–196. doi:10.1007/s40292–016–0143–6

49. Verberk WJ, Kessels AGH, Thien T. Telecare is a valuable tool for hypertension management, a systematic review and metaanalysis. Blood Press Monit. 2011;16(3):149–155. doi:10.1097/MBP. 0b013e328346e092

50. Omboni S, Guarda A. Impact of home blood pressure telemonitoring and blood pressure control: a meta-analysis of randomized controlled studies. Am J Hypertens. 2011; 24(9): 989– 998. doi:10.1038/ajh.2011.100

51. Omboni S, Sala E. The pharmacist and the management of arterial hypertension: the role of blood pressure monitoring and telemonitoring. Exp Rev Cardiovasc Ther. 2015;13(2):209–221. doi:10.1586/14779072.2015.1001368

52. Bray EP, Jones MI, Banting M, Greenfield S, Hobbs FD, Little P et al. Performance and persistence of a blood pressure selfmanagement intervention: Telemonitoring and Self-Management in Hypertension (TASMINH2) Trial. J Hum Hypertens. 2015;29 (7):436–441. doi:10.1038/jhh.2014.108

53. Granger BB, Hayden BB. Medication adherence: emerging use of technology. Curr Opin Cardiol. 2011;26(4):279–287. doi:10.1097/HCO.0b013e328347c150

54. Nguyen TMU, La Caze M, Cottrell N. What are validated selfreport adherence scales really measuring?: a systematic review. Br J Clin Pharmacol. 2014;77(3):427–445. doi:10.1111/bcp.12194

55. Bosworth HB, Powers BJ, Olsen MK, McCant F, Grubber J, Smith V et al. Home blood pressure management and improved blood pressure control: results from a randomized controlled trial. Arch Int Med. 2011;171(13):1173–1180. doi:10.1001/archinternmed.2011.276

56. Shea S, Weinstock RS, Teresi JA, Palmas W, Starren J, Cimino JJ et al. A randomized trial comparing telemedicine case management with usual care in older, ethnically diverse, medically underserved patients with diabetes mellitus: 5 year results of the IDEATel study. J Am Med Informatics Assoc: JAMIA. 2009;16 (4):446–456. doi:10.1197/jamia.M3157

57. Rogers MA, Small D, Buchan DA, Butch CA, Stewart CM, Krenzer BE et al. Home monitoring service improves mean arterial pressure in patients with essential hypertension. a randomized, controlled trial. Ann Int Med. 2001;134(11):1024–1032.

58. Widmer RJ, Collins NM, Collins CS, West CP, Lerman LO, Lerman A. Digital health interventions for the prevention of cardiovascular disease: a systematic review and meta-analysis. Mayo Clin Proc. 2015;90(4):469–480. doi:10.1016/j.mayocp. 2014.12.026

59. Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Int Med. 2013;159 (3):185–194. doi:10.7326/0003-4819-159-3-201308060–00008

60. Friedman RH, Kazis LE, Jette A, Smith MB, Stollerman J, Torgerson J et al. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Am J Hypertens. 2016;9 (4):285–292.

61. Peterson K, McCleery E, Anderson J, Waldrip K, Helfand M. Evidence brief: comparative effectiveness of appointment recall reminder procedures for follow-up appointments. VA evidencebased synthesis program reports. Department of Veterans Affairs (US) 2015.

62. Coelho EB, Moysés NM, Palhares R. Relationship between regular attendance to ambulatory appointments and blood pressure control among hypertensive patients Arq Bras Cardiol. 2005;85 (3):157–161. doi:/S0066–782X2005001600002

63. Pecina JL, Hanson GJ, Van Houten H, Takahashi PY. Impact of telemonitoring on older adults health-related quality of life: The Tele-ERA Study. Quality of Life Research. Int J Quality Life Aspects Treat Care Rehab. 2013;22(9):2315–2321. doi:10.1007/s11136013-0361-5

64. Purcell R., McInnes S, Halcomb EJ. Telemonitoring can assist in managing cardiovascular disease in primary care: a systematic review of systematic reviews. BMC Family Practice. 2014;15: 43. doi:10.1186/1471-2296-15-43

65. Madsen LB, Kirkegaard P, Pedersen EB. Blood pressure control during telemonitoring of home blood pressure. a randomized controlled trial during 6 months. Blood Press. 2008;17(2):78–86. doi:10.1080/08037050801915468

66. Madsen LB, Kirkegaard P, Pedersen EB. Health-Related Quality of Life (SF-36) during telemonitoring of home blood pressure in hypertensive patients: a randomized, controlled study. Blood Press. 2008;17(4):227–232. doi:10.1080/0803705080 2433701

67. Parati G, Omboni S, Albini F, Piantoni L, Giuliano A, Revera M et al. Home blood pressure telemonitoring improves hypertension control in general practice. The TeleBPCare Study. J Hypertens. 2009;27(1):198–203.

68. Reed SD, Li Y, Oddone EZ, Neary AM, Orr MM, Grubber JM et al. Economic evaluation of home blood pressure monitoring with or without telephonic behavioral self-management in patients with hypertension. Am J Hypertens. 2010;23(2):142–148. doi:10.1038/ajh.2009.215

69. Madsen LB, Christiansen T, Kirkegaard P, Pedersen EB. Economic evaluation of home blood pressure telemonitoring: a randomized controlled trial. Blood Press. 2011;20(2):117–125. doi:10.3109/08037051.2010.532306

70. Stoddart A, Hanley J, Wild S, Pagliari C, Paterson M, Lewis S et al. Telemonitoring-based service redesign for the management of uncontrolled hypertension (HINTS): cost and cost-effectiveness analysis of a randomised controlled trial. Br Med J Open. 2015 3 (5). doi:10.1136/bmjopen-2013–002681

71. Telemedicine: opportunities and developments in Member States: report on the second global survey on eHealth. WHO Global Observatory for eHealth. 2009. (Global Observatory for eHealth Series, 2) http://apps.who.int/iris/bitstream/10665/44497/4/9789244564141_rus.pdf

72. Heinzelmann PJ, Lugn NE, Kvedar JC. Telemedicine in the future. J Telemed Telecare. 2005;11(8):384–390.

73. FDA. Mobile Medical Applications Guidance for Industry and Food and Drug Administration Staff. 2015 https://www.fda.gov/downloads/MedicalDevices/…/UCM263366.pdf